Alector (ALEC) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alector's Strategic Advancements and Promising Pipeline: A Buy Rating by Thomas Shrader
TipRanksJan 21 07:56 ET · Ratings
BTIG Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsJan 15 21:32 ET · Ratings
BTIG Remains a Buy on Alector (ALEC)
TipRanksJan 15 20:35 ET · Ratings
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1
Moomoo NewsJan 14 07:31 ET · Ratings
Sell Rating on Alector Due to Delays in Key Data Releases and Low Market Cap
TipRanksJan 13 15:36 ET · Ratings
Express News | Alector Inc - Has $457.2 Million in Cash and Investments as of Sept 30, 2024 Expected to Fund Operations Through 2026
ReutersJan 13 08:02 ET

Comments

102308472

Dec 4, 2024 07:53

$Alector (ALEC.US)$ NO MORE HOPE

Daily Investors

Nov 26, 2024 17:00

🤫

Jaguar8

Nov 25, 2024 15:06

NEWS

$Alector (ALEC.US)$
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefit...

Jaguar8

Sep 19, 2024 07:24

NEWS

$Alector (ALEC.US)$
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...

1

Jaguar8

Jul 28, 2024 07:06

NEWS

$Alector (ALEC.US)$
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
Key point...

1

ALEC Alector

Trade Overview

Capital Trend

News

Comments

Trending Stocks